发明名称 |
SLE-DC-MEDIATED ENHANCED IgG- AND IgA-SECRETING B CELL RESPONSES |
摘要 |
The present invention provides a method for treating a patient at risk for or diagnosed systemic lupus erythematosus (SLE) by determining the overall expression of syndecan-1 in one or more cells of a patient suspected of having SLE; and predicting the efficacy of a therapy with a pharmaceutical agent for treating the patient, wherein a decrease in the overall expression of syndecan-1 in the patient cells when compared to the expression of syndecan-1 in normal cells indicates a predisposition to responsiveness to anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the pharmaceutical agent to the patient. |
申请公布号 |
US2012308578(A1) |
申请公布日期 |
2012.12.06 |
申请号 |
US201213489851 |
申请日期 |
2012.06.06 |
申请人 |
OH SANGKON;PASCUAL MARIA VIRGINIA;BANCHEREAU JACQUES F.;COQUERY CHRISTINE MOREL;JOO HYEMEE;BAYLOR RESEARCH INSTITUTE |
发明人 |
OH SANGKON;PASCUAL MARIA VIRGINIA;BANCHEREAU JACQUES F.;COQUERY CHRISTINE MOREL;JOO HYEMEE |
分类号 |
G01N33/566;A61K39/395;A61P19/04;C12Q1/68;G01N21/64;G01N27/62 |
主分类号 |
G01N33/566 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|